Abstract
In the past decade there has been a tremendous increase in the use of animal models of acute ischaemic stroke to screen for neuroprotective agents. Whilst we await the results of completed Phase III trials of some of these agents, it is timely to review the current status of global and focal ischaemic models. This review provides a summary of the most commonly used models together with their advantages and disadvantages for drug screening.